Cargando…

The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease

OBJECTIVE: To analyze the prevalence, associated comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease and to provide a reference for its prevention and treatment. MATERIALS AND METHODS: Firstly, to screen data obtained from the physical examinations of individ...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Ning, Deng, Jiang, Wang, Jinhai, Zhou, Zhihua, Yao, Cong, Zhou, Mimi, Xing, Xin, Wang, Qian, Lu, Xiaolan, Shi, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705575/
https://www.ncbi.nlm.nih.gov/pubmed/36457563
http://dx.doi.org/10.3389/fmed.2022.1038475
_version_ 1784840314865844224
author Gao, Ning
Deng, Jiang
Wang, Jinhai
Zhou, Zhihua
Yao, Cong
Zhou, Mimi
Xing, Xin
Wang, Qian
Lu, Xiaolan
Shi, Haitao
author_facet Gao, Ning
Deng, Jiang
Wang, Jinhai
Zhou, Zhihua
Yao, Cong
Zhou, Mimi
Xing, Xin
Wang, Qian
Lu, Xiaolan
Shi, Haitao
author_sort Gao, Ning
collection PubMed
description OBJECTIVE: To analyze the prevalence, associated comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease and to provide a reference for its prevention and treatment. MATERIALS AND METHODS: Firstly, to screen data obtained from the physical examinations of individuals conducted in the Second Affiliated Hospital of Xi’an Jiaotong University in 2021, subjects with complete data of abdominal ultrasonography, body mass index, age and sex were selected to analyze the prevalence of fatty liver disease and non-obese fatty liver disease. Secondly, to screen non-obese subjects who had data for triglycerides, fasting blood glucose, and so on, to analyze the complications, influencing factors, and identifying factors of non-obese fatty liver disease. RESULTS: The prevalence of fatty liver disease was 27.8% (18,416/66,221), including 33.9% (11,921/35,131) in males and 20.9% (6,495/31,090) in females, revealing that the prevalence was significantly higher in males than in females (P < 0.001). There were 40,673 non-obese subjects screened in total, and the prevalence of non-obese fatty liver disease was 13.0% (5,307/40,673). The prevalence of non-obese fatty liver disease was 13.3% (2,208/16,572) in males and 12.9% (3,099/24,101) in females; the difference was not statistically significant (P = 0.17). The serum triglycerides level was elevated in 54.2% of subjects with non-obese fatty liver disease, and this was the most common abnormal metabolic index accompanying the disease. Logistic regression analysis showed that gender, age, body mass index, blood pressure, alanine aminotransferase, aspartate aminotransferase, fasting blood glucose, triglycerides, total cholesterol, and serum uric acid were independent risk factors for non-obese fatty liver disease (P < 0.001). For triglycerides, the area under the receiver operating characteristic curve in predicting non-obese fatty liver disease was the greatest (0.806). CONCLUSION: The prevalence of fatty liver disease and non-obese fatty liver disease determined by the physical examination of individuals was high, and the triglycerides is likely to be useful for the extensive screening of non-obese fatty liver disease.
format Online
Article
Text
id pubmed-9705575
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97055752022-11-30 The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease Gao, Ning Deng, Jiang Wang, Jinhai Zhou, Zhihua Yao, Cong Zhou, Mimi Xing, Xin Wang, Qian Lu, Xiaolan Shi, Haitao Front Med (Lausanne) Medicine OBJECTIVE: To analyze the prevalence, associated comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease and to provide a reference for its prevention and treatment. MATERIALS AND METHODS: Firstly, to screen data obtained from the physical examinations of individuals conducted in the Second Affiliated Hospital of Xi’an Jiaotong University in 2021, subjects with complete data of abdominal ultrasonography, body mass index, age and sex were selected to analyze the prevalence of fatty liver disease and non-obese fatty liver disease. Secondly, to screen non-obese subjects who had data for triglycerides, fasting blood glucose, and so on, to analyze the complications, influencing factors, and identifying factors of non-obese fatty liver disease. RESULTS: The prevalence of fatty liver disease was 27.8% (18,416/66,221), including 33.9% (11,921/35,131) in males and 20.9% (6,495/31,090) in females, revealing that the prevalence was significantly higher in males than in females (P < 0.001). There were 40,673 non-obese subjects screened in total, and the prevalence of non-obese fatty liver disease was 13.0% (5,307/40,673). The prevalence of non-obese fatty liver disease was 13.3% (2,208/16,572) in males and 12.9% (3,099/24,101) in females; the difference was not statistically significant (P = 0.17). The serum triglycerides level was elevated in 54.2% of subjects with non-obese fatty liver disease, and this was the most common abnormal metabolic index accompanying the disease. Logistic regression analysis showed that gender, age, body mass index, blood pressure, alanine aminotransferase, aspartate aminotransferase, fasting blood glucose, triglycerides, total cholesterol, and serum uric acid were independent risk factors for non-obese fatty liver disease (P < 0.001). For triglycerides, the area under the receiver operating characteristic curve in predicting non-obese fatty liver disease was the greatest (0.806). CONCLUSION: The prevalence of fatty liver disease and non-obese fatty liver disease determined by the physical examination of individuals was high, and the triglycerides is likely to be useful for the extensive screening of non-obese fatty liver disease. Frontiers Media S.A. 2022-11-15 /pmc/articles/PMC9705575/ /pubmed/36457563 http://dx.doi.org/10.3389/fmed.2022.1038475 Text en Copyright © 2022 Gao, Deng, Wang, Zhou, Yao, Zhou, Xing, Wang, Lu and Shi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Gao, Ning
Deng, Jiang
Wang, Jinhai
Zhou, Zhihua
Yao, Cong
Zhou, Mimi
Xing, Xin
Wang, Qian
Lu, Xiaolan
Shi, Haitao
The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease
title The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease
title_full The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease
title_fullStr The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease
title_full_unstemmed The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease
title_short The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease
title_sort prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705575/
https://www.ncbi.nlm.nih.gov/pubmed/36457563
http://dx.doi.org/10.3389/fmed.2022.1038475
work_keys_str_mv AT gaoning theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT dengjiang theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT wangjinhai theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT zhouzhihua theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT yaocong theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT zhoumimi theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT xingxin theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT wangqian theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT luxiaolan theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT shihaitao theprevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT gaoning prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT dengjiang prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT wangjinhai prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT zhouzhihua prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT yaocong prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT zhoumimi prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT xingxin prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT wangqian prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT luxiaolan prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease
AT shihaitao prevalencecomorbiditiesinfluencingfactorsandidentifyingfactorsofnonobesefattyliverdisease